部份中文拉诺康唑处方资料（仅供参考）
药品英文名
Lanoconazole
药品别名
兰诺康唑、拉诺康唑、Latoconazole
药物剂型
乳膏剂：l%(10g/支、20g/支)；溶液剂：1%(10ml)。
药理作用
本品是一种咪唑类强效局部抗真菌剂。对许多致病真菌都有效，包括多种皮肤真菌病；对多种发癣尤为有效，最低抑菌浓度0.02～3.1μg/ml。其作用机制为抑制真菌麦角甾醇合成。作用强度比联苯苄唑强25倍以上；抗丝状真菌(包括皮肤真菌类和二形真菌)的作用较克霉唑强64倍。与克霉唑和联苯苄唑一样，本品在体外的活性因接种物的体积和加人血清而降低，如添加尿素则活
药动学
大鼠单次或重复皮下注射5mg/kg。单次给药后，血液和血浆浓度达峰时间9h，峰浓度分别为0.31μg/ml和4.5μg/mlt1/2分别为30h和25h；终末t1/2分别为8.8d和4.2d。单剂量给药后168h，主要通过尿(28.2%)和粪(67.4%)排泄，48h内经胆汁排泄量达57.7%。单剂量给药9h后，大多数组织浓度达到峰值，然后逐渐下降。重复用药后皮肤吸收率随重复用药而减少。
适应证
脚癣(足癣)、体癣、股癣、念珠菌病如擦烂、指(趾)间糜烂、甲周炎及花斑癣(花斑糠疹)。
禁忌证
注意事项
1.用药期间患部及鞋袜衣物应保持清洁卫生。
2.本品不可用于严重的糜烂创面，慎用于皲裂创面，不可用于结膜和角膜感染。
不良反应
主要为皮炎、皲裂、干燥、小水疱、肿胀、刺激感及瘙痒等。
用法用量
局部外用：每天一次，足癣连用4周性增强。pH值对本品的活性无显著影响。体癣、念珠菌病和花斑癣患者连用2周。
原处方资料附件：http://www.info.pmda.go.jp/go/pack/2655710M1034_1_05/
Usefulness of Lanoconazole (Astat®) cream in the treatment of hyperkeratotic type tinea pedis. Comparative study of monotherapy and combination therapy with 10% Urea Ointment (Pastaron®)
Abstract
Summary  Hyperkeratotic type tinea pedis is a refractory type of superficial dermatomycosis.
Treatment for hyperkeratotic type tinea pedis is mainly with oral antimycotics, such as griseofulvin, and healing is generally considered to be difficult with only topical antimycotics.
In this randomized comparative study, the usefulness of a topical application of 1% lanoconazole cream (Astat®) monotherapy (group I) was compared with that of combination therapy with 1% lanoconazole cream and 10% urea ointment (Pastaron®) (group II) in a series of patients with hyperkeratotic type tinea pedis.
The clinical improvement rates (percentage of ‘marked improvement’ plus ‘moderate improvement’) was 70.0% in group I and 95.7% in group II.
The fungal eradication rate was 5.0% in group I and 43.5% in group II after 4 weeks of treatment, and was 70.0% and 95.7% after 12 weeks of treatment, respectively.
The usefulness rate (percentage of ‘very useful’ plus ‘useful’) was 70% in group I and 95.7% in group II.
Both lanoconazole monotherapy and the combination therapy with 10% urea ointment were highly effective and safe.
Both treatments should be recommended for patients with hyperkeratotic type tinea pedis for whom an oral treatment is not appropriate or for whom a sufficient improvement with oral medications cannot be expected.